DGCR2

Across TCGA pan-cancer cohorts, DGCR2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of DGCR2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where DGCR2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types DGCR2 is over-expressed in tumor, although a few such as HNSC and PDAC show the opposite, repressed pattern.

LUAD, HNSC, and PDAC are the cancer types where DGCR2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DGCR2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	II,III,IV	+0.291	<.001	6	view →
HNSC	All	All	−0.546	<.001	5	view →
PDAC	Male	All	−0.876	.006	3	view →
LSCC	Female	II,III,IV	+0.299	.015	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

DGCR2–LUAD

Open the LUAD breakdown →